VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH

Vaxess Technologies is to receive US Biomedical Advanced Research and Development Authority (BARDA) funding to demonstrate the feasibility of its MIMIX microneedle patch technology for a covid-19 vaccine, with the aim of designing and developing a scaled manufacturing process for a single-dose, refrigeration-free “combination seasonal protection patch”, incorporating covid-19 + seasonal influenza protection.

The funding for Vaxess is part of BARDA’s efforts to evaluate innovative vaccination technologies for covid-19.

The MIMIX patch is shelf stable and can be self-applied, both critical attributes for pandemic response. It uses sustained-release technology to deliver medicines and vaccines through silk microneedles that dissolve at a precise rate in the skin, releasing their treatment at its most effective dose for the most effective length of time.

MIMIX, so named because it achieves a delivery rate for optimal efficacy by mimicking the prolonged exposure period that occurs during a natural infection, is virtually painless and it is removed from the skin a few minutes after application, while the medication continues to be delivered.

Link to Press Release

See what ondrugdelivery's readers and contributors think


Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.


Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.


Abby Lockwood Opus Strategy photo
Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.


Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.


Top